Published in Medical Patent Week, August 24th, 2008
"In the past few months, we have made some exciting progress across our clinical programs," said Michael N. Chang, Ph.D., Optimer's President and CEO. "Recently, we reported positive top-line data from the first Prulifloxacin Phase 3 study for the treatment of infectious diarrhea....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Week